<DOC>
	<DOC>NCT02552888</DOC>
	<brief_summary>The proposed randomized controlled trial will test the safety and efficacy of combination therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among patients with chronic kidney disease.</brief_summary>
	<brief_title>Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial</brief_title>
	<detailed_description>The proposed randomized controlled trial will test the safety and efficacy of combination therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among patients with chronic kidney disease. Investigators will recruit 70 albuminuric CKD patients and randomly assign participants to combination therapy with sodium nitrite and isoquercetin or placebo for three months.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Men and women aged 2174 years old with any race/ethnicity background CKD as defined by an eGFR &lt;60 ml/min/1.73 m2 or urinary albumin to creatinine ratio ≥ 30 mg/g or protein to creatinine ratio ≥150 mg/g. Systolic BP≥120 and &lt;180 mmHg and/or diastolic BP≥70 and &lt;110 mmHg Allergic to organic nitrite, isoquercetin, niacin, or vitamin C Institutionalized (e.g., prisoner, nursing home or skilled nursing facility resident) Unable or unwilling to give consent Known HIV infection and/or AIDS Pregnant or lactating women Currently on dialysis Previous or current organ or bone marrow transplant Receiving immunosuppressive treatment or other immunotherapy Receiving chemotherapy or alkylating agents for systemic cancer Recent acute myocardial infarction, cerebrovascular accidence or transient ischemic attack, or hospitalization in 3 months Acute kidney injury within the previous 3 months Currently taking a phosphodiesterase5 enzyme inhibitor, such as Viagra History of chronic headaches Chronically receiving fluoroguinolones, cyclosporin (neural, sandimmune), nitrate drug, NSAIDS ( except aspirin ≤ 81 mg daily), allopurinol or uloric, meperidine and related central nervous system (CNS) depressants, oral glucocorticoids, and not willing or able to stop during study period. Active infection (i.e. systemic or osteomyelitis) Class III or IV heart failure History of hemolytic anemia including sickle cell disease Hemoglobin &lt;10 History of chronic obstructive pulmonary disease (COPD) Have a positive screen for glucose6phosphate dehydrogenase (G6PD) deficiency at screening Involvement in other clinical trials Current alcohol or other substance abuse Current smokers Unwillingness to stop flavonoid supplementation Unwillingness to stop nitrate and/or nitrite supplementation</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Endothelial Dysfunction</keyword>
	<keyword>Inflammation</keyword>
</DOC>